Peptides for Muscle Soreness — Evidence-Based Overview

How peptide Targets Peptides for Muscle Soreness

Muscle soreness after exercise — particularly delayed onset muscle soreness (DOMS) — results from exercise-induced muscle damage (EIMD): micro-tears in muscle fibers, disrupted sarcomeres, and the subsequent inflammatory and repair cascade. DOMS typically peaks 24-72 hours after unaccustomed eccentric exercise and involves neutrophil infiltration, inflammatory cytokine release, oxidative stress, and satellite cell activation for repair. Peptides relevant to muscle soreness work through anti-inflammatory pathways, growth factor modulation, and tissue repair acceleration.

BPC-157 is the most discussed peptide for muscle recovery in the sports community. Its preclinical evidence includes accelerated muscle healing after crush and laceration injuries, which involves upregulation of growth hormone receptors in muscle tissue and modulation of nitric oxide pathways. While DOMS is not a traumatic muscle injury, the inflammatory and repair biology overlaps. TB-500 (Thymosin Beta-4) promotes cell migration and reduces inflammation, and is frequently stacked with BPC-157 for recovery protocols. Growth hormone secretagogues — Ipamorelin, GHRP-6, GHRP-2, and MK-677 (Ibutamoren) — are widely used for their potential to enhance recovery through elevated GH and IGF-1, which support muscle protein synthesis and tissue repair. GH's role in recovery is physiologically established, though whether supraphysiological GH levels from secretagogues meaningfully accelerate DOMS resolution beyond natural recovery is less clear.

SS-31 (Elamipretide) targets mitochondrial function and reduces oxidative stress — a significant component of exercise-induced muscle damage. Its mechanism is particularly relevant for the metabolic stress component of DOMS. MGF (Mechano Growth Factor) is an IGF-1 splice variant specifically expressed in mechanically damaged muscle tissue that promotes satellite cell activation and muscle repair. Collagen peptides, while not directly targeting muscle fibers, support the connective tissue component of muscle recovery — tendons, fascia, and the extracellular matrix — which are also stressed during intense exercise. It is worth noting that some degree of muscle soreness is a normal part of the adaptive process to training. Completely eliminating the inflammatory response may theoretically blunt training adaptations, though this concern is more relevant to high-dose anti-inflammatory drugs (NSAIDs) than to the modest anti-inflammatory effects of most peptides.